|

Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer

RECRUITINGSponsored by AbbVie
Actively Recruiting
SponsorAbbVie
Started2026-10-21
Est. completion2030-04
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted

Summary

Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine. Mirvetuximab soravtansine (MIRV) is an approved antibody-drug conjugate being studied for the treatment of FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer. Adult participants with FRα-positive platinum-resistant cancer who have received 1-3 prior treatment lines and are scheduled to receive MIRV as monotherapy will be enrolled. Approximately 500 participants will be enrolled at sites globally. Participants will receive intravenous infusions of mirvetuximab soravtansine as monotherapy according to the local product label and treating physician's decision. The total study duration per participant may be up to 18 months of follow-up. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Participants scheduled to be treated with mirvetuximab soravtansine in accordance with the local label, with treatment decision made independently before study enrollment
* Signed informed consent and willingness to comply with study requirements including patient-reported outcome data collection

Exclusion Criteria:

* Any condition included in the contraindications section of the approved local mirvetuximab soravtansine label
* Participation in a concurrent interventional clinical trial from enrollment throughout the study
* Unwillingness or inability to comply with study requirements

Conditions4

CancerPlatinum-Resistant FRα-Positive Fallopian Tube CancerPlatinum-Resistant FRα-Positive Ovarian CancerPlatinum-Resistant FRα-Positive Peritoneal Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.